5,501 Shares in Unum Group (NYSE:UNM) Acquired by Sharpepoint LLC

Sharpepoint LLC bought a new position in shares of Unum Group (NYSE:UNM - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 5,501 shares of the financial services provider's stock, valued at approximately $402,000.

Other hedge funds also recently added to or reduced their stakes in the company. Barrett & Company Inc. lifted its holdings in shares of Unum Group by 300.0% in the 4th quarter. Barrett & Company Inc. now owns 396 shares of the financial services provider's stock valued at $29,000 after buying an additional 297 shares during the period. Kestra Investment Management LLC purchased a new position in Unum Group during the fourth quarter valued at approximately $38,000. Millstone Evans Group LLC purchased a new stake in Unum Group in the 4th quarter worth approximately $45,000. Versant Capital Management Inc grew its stake in shares of Unum Group by 26.4% during the 4th quarter. Versant Capital Management Inc now owns 766 shares of the financial services provider's stock worth $56,000 after purchasing an additional 160 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Unum Group during the 3rd quarter valued at approximately $58,000. 86.57% of the stock is owned by institutional investors and hedge funds.

Unum Group Price Performance

UNM stock traded down $0.40 during trading on Friday, hitting $78.52. The stock had a trading volume of 556,771 shares, compared to its average volume of 1,302,600. The stock has a market cap of $13.84 billion, a price-to-earnings ratio of 8.29, a price-to-earnings-growth ratio of 1.14 and a beta of 0.46. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.28 and a current ratio of 0.29. The company's 50 day moving average price is $77.97 and its two-hundred day moving average price is $73.83. Unum Group has a 1-year low of $48.38 and a 1-year high of $84.48.

Unum Group (NYSE:UNM - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The financial services provider reported $2.03 earnings per share for the quarter, missing analysts' consensus estimates of $2.14 by ($0.11). Unum Group had a net margin of 13.81% and a return on equity of 14.91%. On average, sell-side analysts forecast that Unum Group will post 9.14 EPS for the current fiscal year.

Unum Group Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 16th. Stockholders of record on Friday, April 25th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 2.14%. The ex-dividend date is Friday, April 25th. Unum Group's dividend payout ratio (DPR) is 17.74%.

Unum Group declared that its Board of Directors has authorized a stock repurchase program on Tuesday, February 18th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the financial services provider to purchase up to 7.4% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's management believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Piper Sandler lifted their target price on shares of Unum Group from $87.00 to $92.00 and gave the company an "overweight" rating in a research report on Wednesday, April 2nd. Raymond James upgraded Unum Group from a "market perform" rating to a "strong-buy" rating and set a $108.00 price objective for the company in a research note on Wednesday, March 5th. UBS Group raised their target price on Unum Group from $75.00 to $91.00 and gave the company a "neutral" rating in a research report on Wednesday, April 2nd. StockNews.com lowered Unum Group from a "buy" rating to a "hold" rating in a research note on Friday, March 7th. Finally, JPMorgan Chase & Co. increased their price objective on Unum Group from $81.00 to $87.00 and gave the company a "neutral" rating in a research note on Wednesday, April 2nd. Five analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $88.36.

Insider Activity

In related news, CEO Richard P. Mckenney sold 50,000 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $81.99, for a total value of $4,099,500.00. Following the sale, the chief executive officer now directly owns 980,637 shares of the company's stock, valued at approximately $80,402,427.63. This trade represents a 4.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Lisa G. Iglesias sold 7,000 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $82.75, for a total transaction of $579,250.00. Following the transaction, the executive vice president now directly owns 31,284 shares of the company's stock, valued at $2,588,751. This trade represents a 18.28 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.93% of the company's stock.

Unum Group Company Profile

Unum Group, together with its subsidiaries, provides financial protection benefit solutions primarily in the United States, the United Kingdom, Poland, and internationally. It operates through Unum US, Unum International, Colonial Life, and Closed Block segment. The company offers group long-term and short-term disability, group life, and accidental death and dismemberment products; supplemental and voluntary products, such as individual disability, voluntary benefits, and dental and vision products; and accident, sickness, disability, life, and cancer and critical illness products.